HC Wainwright Has Negative Estimate for AGIO FY2026 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – HC Wainwright decreased their FY2026 earnings per share estimates for Agios Pharmaceuticals in a report released on Tuesday, July 21st. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings of ($6.84) per share for the year, down from their previous estimate of ($6.77). HC Wainwright currently has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.33) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.60) EPS, FY2027 earnings at ($5.35) EPS, FY2028 earnings at ($4.15) EPS, FY2029 earnings at ($2.29) EPS and FY2030 earnings at $0.64 EPS.

A number of other equities analysts have also weighed in on AGIO. Bank of America boosted their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. decreased their target price on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Thursday, June 11th. Truist Financial boosted their target price on Agios Pharmaceuticals from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Royal Bank Of Canada upped their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $42.78.

Agios Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ AGIO opened at $36.28 on Thursday. The firm has a 50-day simple moving average of $33.73 and a 200-day simple moving average of $30.63. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -5.00 and a beta of 0.54. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The company had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.30 million. The business’s revenue was up 137.7% compared to the same quarter last year.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently bought and sold shares of AGIO. Bellevue Group AG grew its stake in shares of Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after buying an additional 124,586 shares during the period. State Street Corp grew its position in Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after acquiring an additional 845,433 shares during the period. Erste Asset Management GmbH grew its position in Agios Pharmaceuticals by 1.4% in the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after acquiring an additional 40,000 shares during the period. Wellington Management Group LLP increased its stake in Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after acquiring an additional 2,049,287 shares during the last quarter. Finally, Commodore Capital LP increased its stake in Agios Pharmaceuticals by 6.4% during the second quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company’s stock worth $77,330,000 after acquiring an additional 140,000 shares during the last quarter.

Key Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $52 price target on Agios, while lifting multiple long-term earnings estimates for 2027–2030. The firm also published a note saying AGIO appears positioned to beat upcoming earnings expectations, which can support investor sentiment ahead of the Q2 report.
• Neutral Sentiment: The updated analyst forecast for FY2026 was slightly worse, with HC Wainwright trimming its EPS estimate, but the broader message remained constructive because the firm still expects profitability to improve over time.
• Negative Sentiment: Recent news that Agios scrapped the tebapivat sickle cell disease program continues to weigh on the stock. The company ended development after phase II data showed target engagement but not enough clinical differentiation, raising concerns about pipeline execution.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.